Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -3% Improvement Relative Risk HCQ for COVID-19  Auld et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 217 patients in the USA No significant difference in mortality c19hcq.org Auld et al., Critical Care Medicine, Apr 2020 Favors HCQ Favors control

ICU and ventilator mortality among critically ill adults with COVID-19

Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
Retrospective 217 critically ill patients, 114 receiving HCQ, showing no significant difference in mortality.
risk of death, 2.8% higher, RR 1.03, p = 1.00, treatment 33 of 114 (28.9%), control 29 of 103 (28.2%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Auld et al., 26 Apr 2020, retrospective, USA, peer-reviewed, 14 authors.
This PaperHCQAll
ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019*
MD, MSc Sara C Auld, MD Mark Caridi-Scheible, MD James M Blum, MPH Chad Robichaux, MD, MSc Colleen Kraft, MD, MSc Jesse T Jacob, MD Craig S Jabaley, PA David Carpenter, PhD, RN Roberta Kaplow, MD, MPH Alfonso C Hernandez-Romieu, MD Max W Adelman, MD, MSc Greg S Martin, MD Craig M Coopersmith, MD, PhD David J Murphy
Critical Care Medicine, doi:10.1097/ccm.0000000000004457
Patients: Adults greater than or equal to 18 years old with confirmed severe acute respiratory syndrome-CoV-2 disease who were admitted to an ICU during the study period. Interventions: None. Measurements and Main Results: Among 217 critically ill patients, mortality for those who required mechanical ventilation was 35.7% (59/165), with 4.8% of patients (8/165) still on the ventilator at the time of this report. Overall mortality to date in this critically ill cohort is 30.9% (67/217) and 60.4% (131/217) patients have survived to hospital discharge. Mortality was significantly associ-ated with older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure Assessment score, lower Pao 2 / Fio 2 ratio, higher d-dimer, higher C-reactive protein, and receipt of mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy. Conclusions: Despite multiple reports of mortality rates exceeding 50% among critically ill adults with coronavirus disease 2019, particularly among those requiring mechanical ventilation, our early experience indicates that many patients survive their critical illness. (Crit Care Med 2020; 48:e799-e804)
For information regarding this article, E-mail: david.j.murphy@emory.edu The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References
Adelman, Arno, Auld, Barnes, Bender et al., We would like to extend our most profound thanks and gratitude to our colleagues in the Emory Critical Care Center and Emory Healthcare who have worked so hard to provide excellent clinical care during this global pandemic. Emory COVID-19 Quality and Clinical Research Collaborative Members, REFERENCES
Arentz, Yim, Klaff, Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State, JAMA
Begley, With Ventilators Running Out, Doctors Say the Machines Are Overused for Covid-19
Bellani, Laffey, Pham, ESICM Trials Group: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries, JAMA
Bhatraju, Ghassemieh, Nichols, Covid-19 in critically ill patients in the Seattle region -case series, New Engl J Med
Domínguez-Cherit, Lapinsky, Macias, Critically ill patients with 2009 influenza A(H1N1) in Mexico, JAMA
Dondorp, Hayat, Aryal, Respiratory support in novel coronavirus disease (COVID-19) patients, with a focus on resource-limited settings, Am J Trop Med Hyg
Estenssoro, Ríos, Apezteguía, Pandemic 2009 influenza A in Argentina, Am J Respir Crit Care Med
Hamilton, Ventilators Are No Panacea for Critically Ill COVID-19 Patients
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ravani, Allday, Some Doctors Question Wisdom of Using Ventilators on Coronavirus Patients
Richardson, Hirsch, Narasimhan, and the Northwell COVID-19 Research Consortium: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A singlecentered, retrospective, observational study, Lancet Respir Med
Zambon, Vincent, Mortality rates for patients with acute lung injury/ARDS have decreased over time, Chest
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit